Kirsten Kaiser
Research Subjects
Kirsten Kaiser has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Papi
University of Ferrara, S. Anna University Hospital, Ferrara, Italy
1 shared publication - Anthony D. D'Urzo
University of Toronto, Toronto, Canada
1 shared publication - David Price
Observational and Pragmatic Research Institute Singapore Singapore
1 shared publication - Joaquin Sastre
Ciber de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain
1 shared publication - Mark Lomax
Data Management & Statistics, Mundipharma Research Limited, Cambridge, UK
1 shared publication - Robert A. Nathan
Asthma and Allergy Associates, Colorado Springs, Colorado 80907, USA
1 shared publication
Latest Publications
- 1 February 2015
- Published by Elsevier in Respiratory Medicine
- Vol. 109 (2) , 208-217
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis
- 1 February 2015
- Published by Elsevier in Respiratory Medicine
- Vol. 109 (2) , 208-217
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis
- Open Access
- 18 October 2012
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 12 (1) , 67
Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial
This study investigated the efficacy and safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiform®), administered twice daily (b.i.d.) via a single aerosol inhaler, compared with its individual components administered separately and placebo, in patients with mild-to-moderate asthma.
- 18 October 2012
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 12 (1) , 67
Open AccessSafety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial
This study investigated the efficacy and safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiform®), administered twice daily (b.i.d.) via a single aerosol inhaler, compared with its individual components administered separately and placebo, in patients with mild-to-moderate asthma.